Explainer
Evidence-led entry points for non-clinicians. What is a GLP-1 receptor agonist, what does ATC A10BX mean, why are some peptides legal in Russia but not the EU.
Why the 'Wolverine Stack' Didn't Work
BPC-157 and TB-500, the 'wolverine stack,' carry risks from unverified sourcing and peer-relayed dosing on top of thin human evidence.
CJC-1295 + ipamorelin + BPC-157 frequency
No validated injection schedule exists for CJC-1295, ipamorelin and BPC-157. Here is what published literature covers and where the gaps are.
GLP-1 drugs and erectile dysfunction
A new meta-analysis links GLP-1 drugs like semaglutide and tirzepatide to modest erectile-function gains, though other research disagrees.
GLP-1 Drugs and MASH Fibrosis
GLP-1, dual, and triple agonists are being studied for MASH fibrosis. Here is what biopsy-based trials show, and what remains uncertain.
GLP-1 Drugs and Psoriasis Healthcare Use
A new JEADV letter examines whether GLP-1 and GLP-1/GIP drugs like tirzepatide and semaglutide change healthcare use in psoriasis patients.
GLP-1 drugs and sleep apnoea: the survey
A pan-European survey across 24 ESADA centres maps how sleep physicians are using GLP-1 receptor agonists for OSA, and where practice remains uncoordinated.
Semaglutide and burn pain: a mouse study
A mouse study found spinal semaglutide injections eased burn-injury pain via an opioid pathway. Here is why that is not evidence it treats pain in humans.
MASLD treatment: what a 2026 review found
A Gut and Liver review maps current MASLD treatment options and a growing pipeline, from lifestyle change to GLP-1 agonists and thyroid receptor drugs.
Oral incretin therapies for weight loss
Oral semaglutide and orforglipron bring GLP-1 based weight management into tablet form. Here is what the evidence does and does not show.
Tesamorelin, tirzepatide, and weight loss
A forum question cannot show whether sermorelin changes tirzepatide-related weight loss. Here is what tesamorelin evidence and labeling say.
Tirzepatide for postbariatric hypoglycemia
A three-patient case report found fewer post-meal low-glucose episodes after tirzepatide, but it cannot establish a treatment recommendation.
The trade-offs of widespread GLP-1 use
GLP-1 medicines have strong trial evidence, but widespread use also raises questions about access, marketing, and evidence beyond the headlines.